Precision Medicine in Hematology – Working Conference 2019
Date: 20th to 22nd September 2019
Venue: Van Swieten Festival Hall (Van-Swieten-Gasse 1a, Vienna, Austria)
On September 20th the Working Conference on Precision Medicine in Hematology started in Vienna. The three-day meeting reunited several renowned international experts in the field of applied hematology.
The purpose of the meeting was to discuss definitions, diagnostic approaches and tools as well as new therapeutic concepts in precision medicine and personalized medicine in applied hematology. Additionally, prognostication models and individualized management of patients with rare and complex pathologies and the emerging issues of drug-drug interactions and drug side effects have been discussed.
The first two days were dedicated to an in-depth discussion of the topics mentioned above and were open to the public. Day 3 was closed and dedicated to future collaborations.
The meeting was extremely well received and led to some very fruitful scientific discussions.
Comparative Oncology Mast Cell Meeting 2019
Date: 17th to 18th May 2019
Venue: Aula of the University of Vienna, Campus Vienna and Hotel Regina, Vienna, Austria
On May 17, 2019 the 2nd Comparative Oncology Mast Cell Meeting took place in Vienna at the old General Hospital campus of Vienna. The event entitled “Classification and Management of Mast Cell Neoplasm in Dogs and Humans: A Comparative Oncology Approach” focused on improvement of therapy in both humans and dogs.
The scientific organization team included experts from human and canine oncology research, namely Emir Hadzijusufovic, Michael Willmann and Peter Valent. The closed session on May 18, 2019 took place in Hotel Regina in the 9th district of Vienna and served as a working conference with access to faculty members only. The program on day 1 opened with a session about general data on Mast Cells in Health and Disease. During the rest of the day, experts presented their data on molecular markers, grading systems and treatment strategies in MC neoplasms. In the working conference on day 2, experts from the US and Europe came together to discuss diagnosis, classification, prognostication and management of mast cell tumor in dogs and further to compare management strategies and diagnostic algorithms in the canine and human system. Moreover, the aim of the meeting was to develop consensus criteria for improving the treatment of mast cell tumors in dogs. Social Events, such as welcome reception or faculty dinners accompanied the Comparative Oncology Mast Cell Meeting.
KickOff Meeting – The Children’s Cancer Research Institute (CCRI) Joins as a New Partner in the Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO)
Date: 24th April 2019
Venue: Research Center for Molecular Medicine of the Austrian Academy of Science (CeMM) Building at the Campus of the Medical University of Vienna, Austria
On April 24th 2019 the KickOff Meeting was held to welcome The Children’s Cancer Research Institute (CCRI) as the new partner in the Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO). The year 2019 marks the 11th year since LBI HO, previously known as Ludwig Boltzmann Cluster Oncology (LBI ONC) was established, with the general aim to improve the treatment of hematopoietic neoplasms by identification, targeting and eradication of cancer-initiating and disease-propagating cells, also known as leukemic stem cells in the context of hematologic malignancies. CCRI has been founded in 1988 with the focus on basic, translational and clinical research, as well as improvement of diagnostic and prognostic methods and immunological therapies in childhood cancers.
The new partnership between LBI HO and CCRI will provide a unique platform for further strengthening of collaboration efforts and development of joint projects. Following the welcome notes from Mag. Caludia Lingner, Head of the Ludwig Boltzmann Gesellschaft, Prof. Wolfgang Holter, Head of the CCRI, and Prof. Peter Valent, Director of LBI HO, the program opened with the presentations of the mission, project lines and perspectives for LBI HO and CCRI by Prof. Peter Valent and Prof. Thomas Lion. The meeting continued with scientific presentations held by group leaders, senior scientists and PhD students from the two research institutions, followed by fruitful discussions on future potential for collaborations and further research development. The topics included uncovering resistance mechanisms in myeloid neoplasms, age-related clonal hematopoiesis in the context of cancer, immunotherapeutic approaches for cancer treatment, cancer stem cell characterization and target discovery as well as treatment effects on clonal dynamics of complex cancers. The meeting was accompanied by a social event aimed at networking and continuation of scientific discussion.